Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Zolmitriptan
Drug ID BADD_D02393
Description Zolmitriptan is a member of the triptan class of 5-hydroxytryptamine(5-HT)1B/1D/(1F) receptor agonists used to treat acute migraine.[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. This led to the development of second-generation triptans, including [almotriptan], [eletriptan], [frovatriptan], [naratriptan], [rizatriptan], and zolmitriptan.[A193791] Triptans can be administered alone or in combination with an NSAID like [naproxen], and represent the current "gold standard" for acute migraine treatment.[A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997. It is currently available in both tablet and nasal spray forms.[L12978]
Indications and Usage Zolmitriptan is indicated for the acute treatment of migraine with or without auras in patients aged 18 and over.[L12978]
Marketing Status approved; investigational
ATC Code N02CC03
DrugBank ID DB00315
KEGG ID D00415
MeSH ID C089750
PubChem ID 60857
TTD Drug ID D0NG7O
NDC Product Code 64567-0016; 63548-0101; 64896-681; 64896-682; 64980-256; 68001-250; 72189-435; 65372-1145; 16571-803; 69238-2007; 65977-0050; 67835-5007; 64896-692; 65841-765; 65841-766; 64896-691; 64980-204; 69097-864; 71626-101; 72189-434; 65015-688; 46708-182; 64896-672; 68001-249; 68462-498; 60846-2384; 64896-671; 64980-203; 64980-257; 65841-768; 68382-715; 68462-497; 69097-863; 63548-0102; 63629-9575; 68382-712; 72606-567; 54864-955; 27241-022; 68382-717; 68462-499; 11722-012; 63850-4322; 45802-711; 46708-181; 46708-463; 55700-943; 55700-944; 68382-714; 69238-2006; 55111-800; 27241-021; 46708-462; 60846-2383; 65841-767; 65862-914; 65862-915; 68462-500; 71626-102; 72606-568; 65862-801; 66039-845; 16571-804
UNII 2FS66TH3YW
Synonyms zolmitriptan | 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone | Zomig | AscoTop | Zomigoro | 311C90 | Flezol
Chemical Information
Molecular Formula C16H21N3O2
CAS Registry Number 139264-17-8
SMILES CN(C)CCC1=CNC2=C1C=C(C=C2)CC3COC(=O)N3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diarrhoea07.02.01.0010.005213%
Diarrhoea haemorrhagic24.07.02.004; 07.02.01.002--Not Available
Diplopia17.17.01.005; 06.02.06.002--Not Available
Discomfort08.01.08.0030.001489%Not Available
Disorientation17.02.05.015; 19.13.01.002--Not Available
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
Drug abuse19.07.06.0100.001015%Not Available
Drug ineffective08.06.01.006--Not Available
Drug interaction08.06.03.0010.001354%Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.002--
Dysgeusia07.14.03.001; 17.02.07.0030.002640%
Dysmenorrhoea21.01.01.002--
Dyspepsia07.01.02.0010.002031%
Dysphagia07.01.06.0030.001354%
Dyspnoea02.11.05.003; 22.02.01.004--
Ear pain04.03.01.003--
Ecchymosis01.01.03.001; 24.07.06.002; 23.06.01.001--Not Available
Eczema23.03.04.006--
Electrocardiogram abnormal13.14.05.001--Not Available
Eosinophilia01.02.04.001--
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.003--
Erythema23.03.06.0010.000677%Not Available
Euphoric mood19.04.02.006--
Extrasystoles02.03.02.003--Not Available
Eye pain06.08.03.002--
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.000677%
Facial pain08.01.08.0120.001489%
Fatigue08.01.01.0020.005822%
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 10 Pages